dexamethasone,lenalidomide,carfilzomib,daratumumab
amgen,janssen
['ascent', 'mmsm']
#ash22 #mmsm interesting observation-ascent trial(smoldering myeloma) primary end point:to test null hypothesis that scr proportion is at most 65% and alternate hypothesis of 80% scr at presentation:38% does that mean study failed to meet 1ry endpoint(so far)? 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities